Yadav S et al (2020) Evaluation of germline genetic testing criteria in a hospital-based series of women with breast cancer. J Clin Oncol 38(13):1409–1418

Article  CAS  PubMed  PubMed Central  Google Scholar 

成井, 理., et al., BRCA1/2遺伝学的検査保険適用拡大後の検査施行症例の検討と今後の課題. 日本臨床外科学会雑誌, 2022. 83(8): p. 1381–1392.

Yoshimura A et al (2021) Incidence of contralateral and ipsilateral breast cancers and prognosis in BRCA1/2 pathogenic variant carriers based on the Japanese HBOC consortium registration. J Hum Genet 66(4):379–387

Article  CAS  PubMed  Google Scholar 

Okano M et al (2021) The relationship between BRCA-associated breast cancer and age factors: an analysis of the Japanese HBOC consortium database. J Hum Genet 66(3):307–314

Article  CAS  PubMed  Google Scholar 

Arai M (2021) Hereditary Breast and Ovarian Cancer (HBOC) Database in Japan. In: Nakamura S, Aoki D, Miki Y (eds) Hereditary Breast and Ovarian Cancer : Molecular Mechanism and Clinical Practice. Springer Singapore, Singapore, pp 243–257

Chapter  Google Scholar 

Daly MB et al (2023) NCCN guidelines® insights: genetic/familial high-risk assessment: breast, ovarian, and pancreatic, version 2.2024. J Natl Compr Canc Netw 21(10):1000–1010

Article  CAS  PubMed  Google Scholar 

Momozawa Y et al (2018) Germline pathogenic variants of 11 breast cancer genes in 7,051 Japanese patients and 11,241 controls. Nat Commun 9(1):4083

Article  PubMed  PubMed Central  Google Scholar 

Nakamura S et al (2015) Prevalence and differentiation of hereditary breast and ovarian cancers in Japan. Breast Cancer 22(5):462–468

Article  PubMed  Google Scholar 

Guzmán-Arocho YD et al (2022) Clinicopathological features and BRCA1 and BRCA2 mutation status in a prospective cohort of young women with breast cancer. Br J Cancer 126(2):302–309

Article  PubMed  Google Scholar 

Copson ER et al (2018) Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study. Lancet Oncol 19(2):169–180

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mavaddat N et al (2012) Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev 21(1):134–147

Article  CAS  PubMed  Google Scholar 

Spurdle AB et al (2014) Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. Breast Cancer Res 16(6):3419

Article  PubMed  PubMed Central  Google Scholar 

Stjepanovic N et al (2021) Breast cancer risk after age 60 among BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat 187(2):515–523

Article  CAS  PubMed  Google Scholar 

Paik HJ et al (2021) Clinicopathological features of BRCA1/2 mutation-positive breast cancer. Oncology 99(8):499–506

Article  CAS  PubMed  Google Scholar 

Yamauchi H et al (2018) High rate of occult cancer found in prophylactic mastectomy specimens despite thorough presurgical assessment with MRI and ultrasound: findings from the hereditary breast and ovarian cancer registration 2016 in Japan. Breast Cancer Res Treat 172(3):679–687

Article  PubMed  PubMed Central  Google Scholar 

Nomura H et al (2023) Impact of the coverage of risk-reducing salpingo-oophorectomy by the national insurance system for women with BRCA pathogenic variants in Japan. Sci Rep 13(1):1018

Article  CAS  PubMed  PubMed Central  Google Scholar 

Matsumoto M et al (2025) The impact of public insurance on RRSO for HBOC in Japan: a nationwide data study. J Hum Genet 70(8):421–426

Article  PubMed  PubMed Central  Google Scholar 

Yadav S et al (2023) Contralateral breast cancer risk among carriers of germline pathogenic variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2. J Clin Oncol 41(9):1703–1713

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kuchenbaecker KB et al (2017) Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317(23):2402–2416

Article  CAS  PubMed  Google Scholar 

Assad H et al (2024) Uptake of screening and risk-reducing recommendations among women with hereditary breast and ovarian cancer syndrome due to pathogenic BRCA1/2 variants evaluated at a large urban comprehensive cancer center. Breast Cancer Res Treat 206(2):261–272

Article  CAS  PubMed  Google Scholar 

Lubinski J et al (2024) MRI surveillance and breast cancer mortality in women with BRCA1 and BRCA2 sequence variations. JAMA Oncol 10:493

Article  PubMed  Google Scholar 

Sun J et al (2023) BRCA-CRisk: a contralateral breast cancer risk prediction model for BRCA carriers. J Clin Oncol 41(5):991–999

Article  CAS  PubMed  Google Scholar 

Gaba F et al (2023) Breast cancer risk and breast-cancer-specific mortality following risk-reducing salpingo-oophorectomy in BRCA carriers: a systematic review and meta-analysis. Cancers (Basel). https://doi.org/10.3390/cancers15051625

Article  PubMed  Google Scholar 

Akdeniz D et al (2022) Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: a nationwide cohort study. Breast 61:98–107

Article  PubMed  Google Scholar 

Johnston SRD et al (2020) Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol 38(34):3987–3998

Article  CAS  PubMed  PubMed Central  Google Scholar 

Geyer CE Jr et al (2022) Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. Ann Oncol 33(12):1250–1268

Article  CAS  PubMed  Google Scholar 

Choi YH et al (2021) Association of risk-reducing salpingo-oophorectomy with breast cancer risk in women with BRCA1 and BRCA2 pathogenic variants. JAMA Oncol 7(4):585–592

PubMed  Google Scholar 

Lazzeroni M et al (2023) Randomized placebo controlled trial of low-dose tamoxifen to prevent recurrence in breast noninvasive neoplasia: a 10-year follow-up of TAM-01 study. J Clin Oncol 41(17):3116–3121

Article  CAS  PubMed  Google Scholar 

Fisher B et al (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 90(18):1371–1388

Article  CAS  PubMed  Google Scholar